Frontiers in Immunology (Jan 2021)

COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases

  • Katja Lakota,
  • Katja Lakota,
  • Katja Perdan-Pirkmajer,
  • Katja Perdan-Pirkmajer,
  • Alojzija Hočevar,
  • Alojzija Hočevar,
  • Snezna Sodin-Semrl,
  • Snezna Sodin-Semrl,
  • Žiga Rotar,
  • Žiga Rotar,
  • Saša Čučnik,
  • Saša Čučnik,
  • Polona Žigon,
  • Polona Žigon

DOI
https://doi.org/10.3389/fimmu.2020.611318
Journal volume & issue
Vol. 11

Abstract

Read online

Autoimmune diseases and infections are often closely intertwined. Patients with autoimmune diseases are more susceptible to infections due to either active autoimmune disease or the medications used to treat them. Based on infections as environmental triggers of autoimmunity, an autoimmune response would also be expected in COVID-19. Although some studies have shown the occurance of autoantibodies and the possible development of autoimmune diseases after SARS-CoV-2 infection, current data suggest that the levels of autoantibodies following SARS-CoV-2 infection is comparable to that of some other known infections and that the autoantibodies might only be transient. The risk of SARS-CoV-2 infection in patients with a systemic autoimmune rheumatic disease (SARD) appears slightly higher compared to the general population and the course of COVID-19 disease does not seem to be very different, however, specific therapies such as glucocorticoids and anti-TNF might modulate the risk of hospitalization/death. Cytokine release syndrome is a severe complication in COVID-19. Many drugs used for the treatment of SARD are directly or indirectly targeting cytokines involved in the cytokine release syndrome, therefore it has been suggested that they could also be effective in COVID-19, but more evidence on the use of these medications for the treatment of COVID-19 is currently being collected.

Keywords